Latest Hotspot

Zura Bio Unveils Findings for Tibulizumab (ZB-106) Initiative at EULAR 2024

18 June 2024
3 min read

Zura Bio Limited, an immunology company in the clinical-stage focused on creating innovative dual-pathway antibodies for autoimmune and inflammatory conditions, has recently unveiled positive results from a Phase 1 trial of its leading drug candidate, tibulizumab (ZB-106), aimed at treating Sjogren’s syndrome. Additionally, preclinical findings endorsing the continued development of tibulizumab for rheumatoid arthritis were also disclosed at the Annual European Congress of Rheumatology 2024 held in Vienna.

👇Explore more about this drug by clicking the image below. Gain detailed insights into its R&D Status, Core Patent, Clinical Trials and Global Approval Status. Stay informed and updated.

图形用户界面, 文本, 应用程序, 电子邮件, Teams

描述已自动生成

"Collectively, this dataset contributes to early-phase evidence showing that simultaneously inhibiting IL-17A and BAFF might be a pioneering strategy for autoimmune and inflammatory disorders, where inhibition of a single pathway is currently standard practice," remarked Robert Lisicki, Chief Executive Officer. 

"In Sjogren’s syndrome, the findings illustrate that tibulizumab effectively achieved significant target engagement, reaching near-maximum serum concentrations after single, well-tolerated subcutaneous doses administered at four-week intervals. Additionally, preclinical outcomes suggest that dual-pathway inhibition should be clinically investigated in RA and other autoimmune disorders, expanding the therapeutic potential of tibulizumab," added Lisicki. 

Following tibulizumab administration, serum levels of total IL-17A and BAFF increased, indicating successful target engagement. At dosages of 100 mg Q4W and above, the concentrations of these markers plateaued, implying that near-maximal target engagement was achieved.

Throughout the study, there was a dose-dependent decrease in total B cell counts among all participants, and tibulizumab administration was linked with reduced levels of Th1 cells. Tibulizumab also modulated inflammatory mediators such as serum amyloid A, interleukins 5 and 10, as well as basic fibroblast growth factor. These findings suggest tibulizumab holds therapeutic promise for a range of additional autoimmune conditions.

Tibulizumab, a humanized bispecific dual antagonist antibody, fuses TALTZ® (ixekizumab) with tabalumab, engineered to bind and neutralize IL-17A and BAFF. Tibulizumab is slated to enter Phase 2 clinical trials for systemic sclerosis in Q4 2024 and hidradenitis suppurativa in Q2 2025. Completed tibulizumab studies include Phase 1/1b trials in Sjogren's syndrome and rheumatoid arthritis.

👇Explore the most recent advancements in drug research, indications, organizations, clinical trials, results, and patents related to this target by clicking the image link below. Dive in to gain deeper insights!

图形用户界面, 应用程序

描述已自动生成

According to the data provided by the Synapse Database, As of June 18, 2024, there are 1 investigational drugs for the IL-17A and BAFF targets, including 2 indications, 1 R&D institutions involved, with related clinical trials reaching 4, and as many as 2000 patents.

Tibulizumab targets BAFF and IL-17 for the treatment of immune system diseases, eye diseases, mouth and tooth diseases, as well as skin and musculoskeletal diseases. Its potential to address multiple disease pathways simultaneously makes it a promising candidate for various conditions, pending further development and regulatory approval.

图形用户界面, 文本, 应用程序, 网站

描述已自动生成

Genentech's Columvi Extends Survival in Relapsed/Refractory Large B-cell Lymphoma Trial
Latest Hotspot
4 min read
Genentech's Columvi Extends Survival in Relapsed/Refractory Large B-cell Lymphoma Trial
18 June 2024
Genentech's Phase III STARGLO Trial Shows Columvi Significantly Prolongs Survival in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma.
Read →
Global New Drug Research and Development Progress Weekly Report(6.10-6.16)
Drug Highlight
10 min read
Global New Drug Research and Development Progress Weekly Report(6.10-6.16)
17 June 2024
6.10-6.16 Global Drug R&D Progress & Pharmaceutical Transaction Trends.
Read →
KSQ Therapeutics Initiates Clinical Trials for CRISPR/Cas9 eTIL® Therapy KSQ-001EX with First Patient Dosed
Latest Hotspot
3 min read
KSQ Therapeutics Initiates Clinical Trials for CRISPR/Cas9 eTIL® Therapy KSQ-001EX with First Patient Dosed
17 June 2024
KSQ Therapeutics Begins Clinical Trials with Initial Patient Dosed for CRISPR/Cas9 Modified eTIL® Therapy KSQ-001EX.
Read →
Promising Results from Avidity's Phase 1/2 FORTITUDE™ Trial of AOC 1020: Over 50% DUX4 Gene Reduction and Functional Improvements in FSHD Patients
Latest Hotspot
3 min read
Promising Results from Avidity's Phase 1/2 FORTITUDE™ Trial of AOC 1020: Over 50% DUX4 Gene Reduction and Functional Improvements in FSHD Patients
17 June 2024
Avidity Reveals Remarkable Phase 1/2 FORTITUDE™ Trial Results for AOC 1020 Showing Over 50% Decrease in DUX4 Genes and Functional Improvement Trends in Facioscapulohumeral Muscular Dystrophy Patients.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.